Immunome Current Assets

Immunome (IMNM) currently reports a current assets of $590M as of March 2026. That compares with $320M in the prior-year period — up 83.9% year over year. Use the charts on this page to explore Immunome's current assets history and peer comparisons.

Immunome's current assets increased from $320M to $590M — a 83.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Immunome reported $590M in current assets as of March 2026. That compares with $320M in the prior-year period — up 83.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $590M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Immunome, and consider following IMNM for alerts when major investors trade the stock.

Immunome is classified in the Healthcare sector. On current assets, it currently shows $590M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMNM with unrelated industries.